Unibest

Pharmaceutical intermediates

Darolutamide Intermediates

1 pharmaceutical intermediate for Darolutamide. Indication: Hormone-sensitive prostate cancer; Castration-sensitive prostate cancer; Prost.

提交项目All intermediates

About Darolutamide

Originator
Orion Corporation
Indication
Hormone-sensitive prostate cancer; Castration-sensitive prostate cancer; Prost
Approved Date
07/30/2019
DS/DP
03/25/2030

Available intermediates

1 intermediate currently listed for Darolutamide. Request specifications, documentation or a quotation for any item below.

Darolutamide intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
4-Bromo-2-chlorobenzonitrile154607-01-9//

Other programs under D

Dabigatran EtexilateDabigatran etexilate mesylateDabrafenib MesylateDacomitinibDanicopanDapagliflozinDaridorexant HydrochlorideDasatinib Hydrate

Building toward Darolutamide?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →